SCHEMBL4680306

SCHEMBL4680306

O=C(C=C(O)c1nc[nH]n1)c1ccc(S(=O)(=O)c2ccc(Cl)cc2)o1

nearest known ligand 0.32

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 4/20 0.31
CYP3A4 P08684 1/20 0.31
MAPK1 P28482 1/20 0.31
AKR1B1 P15121 1/20 0.31
TSHR P16473 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KMT2A Q03164 2/20 0.30
MAPT P10636 1/20 0.30
NAMPT P43490 1/20 0.30
TBXA2R P21731 1/20 0.30
SGMS1 Q86VZ5 1/20 0.30
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671017 0.89 HTR2A (0.34) AKR1B1MAPTNAMPTSGMS1
SCHEMBL4676467 0.83 CXCR3 (0.36) ALDH1A1CYP3A4MAPK1AKR1B1TSHR
SCHEMBL4677186 0.82 ALDH1A1 (0.33) ALDH1A1CYP3A4MAPK1AKR1B1L3MBTL1
SCHEMBL4678455 0.81 CHEK2 (0.32) ALDH1A1CYP3A4MAPK1AKR1B1KMT2A
SCHEMBL4678600 0.80 HSD17B10 (0.41) KDM4EALDH1A1TSHRKMT2AMAPT
SCHEMBL4671086 0.78 MAPT (0.39) KDM4EALDH1A1MAPK1MAPTSMN1; SMN2
SCHEMBL4672361 0.78 ALDH1A1 (0.34) KDM4EALDH1A1CYP3A4MAPK1AKR1B1
SCHEMBL4673977 0.78 POLB (0.31) KDM4EALDH1A1CYP3A4MAPK1AKR1B1
SCHEMBL4675358 0.78 ALDH1A1 (0.31) ALDH1A1CYP3A4MAPK1AKR1B1KMT2A
SCHEMBL4674442 0.77 SMN1; SMN2 (0.40) KDM4EALDH1A1CYP3A4MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KDM4E 947/4885ALDH1A1 980/4885CYP3A4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.